TR200002242T2 - 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları. - Google Patents

5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.

Info

Publication number
TR200002242T2
TR200002242T2 TR2000/02242T TR200002242T TR200002242T2 TR 200002242 T2 TR200002242 T2 TR 200002242T2 TR 2000/02242 T TR2000/02242 T TR 2000/02242T TR 200002242 T TR200002242 T TR 200002242T TR 200002242 T2 TR200002242 T2 TR 200002242T2
Authority
TR
Turkey
Prior art keywords
alpha
imidazolinylamino
preparation
adrenoceptor agonists
metabolic stability
Prior art date
Application number
TR2000/02242T
Other languages
English (en)
Turkish (tr)
Inventor
Lee Cupps Thomas
Lee Bogdan Sophie
Nikolaides Nicholas
Ann Gilbert Sheri
Gazda Michael
Lee Martin Dobson Roy
Iii Charles Andrew Cruze
Original Assignee
The Procter &Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter &Gamble Company filed Critical The Procter &Gamble Company
Publication of TR200002242T2 publication Critical patent/TR200002242T2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR2000/02242T 1997-11-24 1998-11-20 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları. TR200002242T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US6670097P 1997-11-25 1997-11-25

Publications (1)

Publication Number Publication Date
TR200002242T2 true TR200002242T2 (tr) 2000-11-21

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02242T TR200002242T2 (tr) 1997-11-24 1998-11-20 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.

Country Status (23)

Country Link
US (1) US6486190B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1037887B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2001524478A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20010032435A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1284073A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE271048T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9815017A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2311344C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO4970802A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69825075T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2223143T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0101469A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL136303A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN190809B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20002655L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ504707A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE133699A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL340711A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2193562C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK7792000A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200002242T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW505642B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1999026942A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456183B2 (en) 2001-04-09 2008-11-25 Novartis Vaccines And Diagnostics, Inc. Guanidino compounds
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
RU2225401C1 (ru) * 2002-09-16 2004-03-10 Катаев Валерий Алексеевич 5(6)-нитро-1-(1,1-диоксотиетанил-3)-2-хлорбензимидазол, проявляющий биологическую активность
US20040167194A1 (en) 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
CN100366603C (zh) * 2003-02-20 2008-02-06 隆萨股份公司 N-取代甲酰胺的制备方法
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PL1761266T3 (pl) * 2004-05-25 2013-09-30 Galderma Pharma Sa Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
RU2306137C1 (ru) * 2005-12-28 2007-09-20 Денис Вячеславович Лисицын Средство для профилактики и лечения гриппа
JP2015517980A (ja) * 2012-02-27 2015-06-25 アイ・セラピーズ・エル・エル・シー 片頭痛の治療のための組成物および方法
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
AU2016365219A1 (en) * 2015-11-30 2018-07-05 Novus Therapeutics, Inc. Compositions and methods for otologic prophylaxis and treatment
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
DE3071229D1 (en) 1979-08-23 1985-12-19 Beecham Group Plc Anti-diarrhoea veterinary composition
US4436913A (en) 1980-09-05 1984-03-13 Siegfried Aktiengesellschaft 1H- and 2H- indazole derivatives
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
TW300219B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-09-14 1997-03-11 Hoechst Ag
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
EP0775134A4 (en) 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
US6486190B1 (en) 2002-11-26
IL136303A0 (en) 2001-05-20
IL136303A (en) 2004-02-08
DE69825075T2 (de) 2005-08-25
NO20002655D0 (no) 2000-05-24
CA2311344C (en) 2006-02-07
KR20010032435A (ko) 2001-04-25
RU2193562C2 (ru) 2002-11-27
HUP0101469A2 (hu) 2001-10-28
PE133699A1 (es) 2000-03-05
HUP0101469A3 (en) 2003-01-28
DE69825075D1 (de) 2004-08-19
CN1284073A (zh) 2001-02-14
WO1999026942A1 (en) 1999-06-03
NZ504707A (en) 2002-11-26
NO20002655L (no) 2000-07-24
SK7792000A3 (en) 2001-01-18
CO4970802A1 (es) 2000-11-07
BR9815017A (pt) 2001-09-11
EP1037887A1 (en) 2000-09-27
EP1037887B1 (en) 2004-07-14
ES2223143T3 (es) 2005-02-16
JP2001524478A (ja) 2001-12-04
WO1999026942A8 (en) 2000-08-03
IN190809B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2003-08-23
ATE271048T1 (de) 2004-07-15
CA2311344A1 (en) 1999-06-03
TW505642B (en) 2002-10-11
PL340711A1 (en) 2001-02-26

Similar Documents

Publication Publication Date Title
TR200002242T2 (tr) 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.
TR200200588T2 (tr) N-pirazol A2A reseptör agonistleri
ATE244715T1 (de) Azol-verbindungen, ihre herstellung und ihre verwendung
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
DE69329727D1 (de) Neue imidazol derivate, ihre herstellung und therapeutische verwendung
CR10167A (es) "uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de dolor"
CY1112377T1 (el) Μεθοδος και συνθεσεις για τη θεραπευτικη aντιμετωπιση των αιματολογικων κακοηθειων
EP1482791A4 (en) ANTIMICROBIAL THERAPEUTIC COMPOSITIONS AND THEIR USE
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
KR880007071A (ko) 1-치환된 이미다졸 및 비-스테로이드계 소염제를 함유하는 조성물
PE20020637A1 (es) Derivados de 5-oxo-pirrolidina como agonistas de prostaglandinas
ATE430743T1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
DE69928226T8 (de) Chemokin rezeptor antagonisten und verwendung
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
ATE366602T1 (de) Festförmiges färbemittel für keratinfasern
MX9303469A (es) Derivados de benzimidazol, procedimiento para su preparacion, composicion farmaceutica que los contiene y procedimiento para preparar de la misma.
MX2009010567A (es) Derivados de imidazolidinona.
MA39043B1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
UY26226A1 (es) 'derivados de aminopirrolidina heterocíclica como agentes melatonergicos'.- ley 17.164.-
IS2143B (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
EA200100852A1 (ru) Производные резорцина
DK2886D0 (da) Dopamin-beta-hydroxylaseinhibitorer
PE20021153A1 (es) 5-[2-BUTOXI-5-(1-HIDROXIETIL)-3-PIRIDINIL]-3-ETIL-2-(1-ETIL-3-AZETIDINIL)-2,6-DIHIDRO-7H-PIRAZOLO[4,3-d]PIRIMIDIN-7-ONA COMO INHIBIDORES DE FOSFODIESTERASAS DE GUANOSIN 3',5'-MONOFOSFATO CICLICO